Hypereosinophilic syndrome

Search Trials
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
Status:
Recruiting
Last Changed:
Aug 7, 2019
First Changed:
Apr 5, 2019
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo
A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
Status:
Withdrawn
Last Changed:
Mar 18, 2019
First Changed:
Nov 27, 2017
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Status:
Not yet recruiting
Last Changed:
Jan 11, 2019
First Changed:
Jan 11, 2019
Disease(s):
BCR-JAK2 Fusion Protein Expression
Intervention(s):
Ruxolitinib
2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
Status:
Completed
Last Changed:
Aug 2, 2012
First Changed:
Jun 6, 2007
Disease(s):
Leukemia
Intervention(s):
2-CdAAra-CG-CSF (Granulocyte colony-stimulating factor)
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
Status:
Completed
Last Changed:
Dec 12, 2013
First Changed:
Jun 5, 2002
Disease(s):
Chronic Myelomonocytic Leukemia
Intervention(s):
Imatinib Mesylate (Gleevec)

Connect. Empower. Inspire.